Journal List > J Korean Ophthalmol Soc > v.53(2) > 1009286

TOOLS
Kim, Kim, Song, and Kim: Retinal Vascular Caliber Changes on OCT after Intravitreal Bevacizumab Injection in Diabetic Macular Edema
Original Article
Journal of the Korean Ophthalmological Society

Journal of the Korean Ophthalmological Society 2012; 53(2): 262-267.

Published online: 15 February 2012

DOI: https://doi.org/10.3341/jkos.2012.53.2.262

Retinal Vascular Caliber Changes on OCT after Intravitreal Bevacizumab Injection in Diabetic Macular Edema

Young Jun Kim, MD1, Hyoung Eun Kim, MD1, Won Kyung Song, MD2, Sung Soo Kim, MD, PhD1

1Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea.

2Department of Ophthalmology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.

Address reprint requests to Sung Soo Kim, MD, PhD. Department of Ophthalmology, Gangnam Severance Hospital, Yonsei University College of Medicine, #211 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea. Tel: 82-2-2019-3443, Fax: 82-2-3463-1049, semekim@yuhs.ac

Received 20 April 2011       Accepted 13 December 2011

Copyright © 2012 The Korean Ophthalmological Society

Abstract

Purpose

To investigate retinal vascular caliber changes with Spectral Domain OCT after intravitreal bevacizumab injection in diabetic macular edema patients.

Methods

Thirty-four eyes of 29 diabetic macular edema patients who were intravitreously injected with bevacizumab (1.25 g/0.05 ml) were studied. Twenty-four fellow eyes of 24 patients with bevacizumab injection were also recruited as a control group. We measured retinal vascular caliber a distance of 0.5-1 disc sizes from the disc margin with Spectral Domain OCT at baseline and 1-month and 3-month follow-up visits. Central macular thicknesses were also measured.

Results

Over the 3 months of study, there was a significant reduction of arteriolar caliber compared to baseline (p = 0.024), There was significant reduction of venular caliber at 1 month (p = 0.001) and 3 months (p = 0.000) compared to baseline. Venular caliber reduction at the 3-month follow-up was significantly correlated with central macular thickness (R = 0.487, p = 0.003).

Conclusions

Retinal venular caliber reduction was significant at 1- and 3-month follow-up, and arteriolar caliber reduction was significant at 3-month follow-up compared to baseline. After 3 months of treatment, venular caliber reduction was correlated with reduction of central macular thickness.

Keywords: Central macular thickness, Retinal arteriolar caliber, Retinal venular caliber

Figures and Tables

Figure 1
Measurement of vascular caliber. At 0.5-1 disc diameter from disc margin, vascular calibers are measured 3 times in arterioles and venules and the average is taken. Top) Main result of Cirrus HD-OCT. Fundus photograph is seen at the upper left of the screen (black arrow). Bottom left) Preoperative measurement of vascular caliber. Bottom center) Vascular calibers are measured at 0.5-1 disc size apart from disc margin. Bottom right) Measurement of vascular caliber at 3 months after intravitreal injection of bevacizumab.
jkos-53-262-g001
Figure 2
Correlations of central macular thickness and retinal vascular caliber after intravitreal bevacizumab injection.
jkos-53-262-g002
Table 1
Baseline characteristics
jkos-53-262-i001

Data are expressed as mean ± SD or number.

DM = diabetes mellitus; IOP = intraocular pressure; CMT = central macular thickness.

Table 2
Retinal vascular caliber and central macular thickness at baseline and after 1 month Intravitreal bevacizumab injection
jkos-53-262-i002

Data are expressed as mean ± SD.

CMT = central macular thickness.

*Measured data before intravitreal bevacizumab injection; †Compared to baseline.

Table 3
Retinal vascular caliber at baseline and 3 months after intravitreal bevacizumab injection
jkos-53-262-i003

Data are expressed as mean ± SD.

CMT = central macular thickness.

*Measured data before intravitreal bevacizumab injection; †Compared to baseline.

References

1. Ferris FL 3rd, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol. 1984. 28:452–461.
2. Kohner EM. Diabetic retinopathy. Clin Endocrinol Metab. 1977. 6:345–375.
3. McDonald HR, Schatz H. Macular edema following panretinal photocoagulation. Retina. 1985. 5:5–10.
4. McDonald HR, Schatz H. Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology. 1985. 92:388–393.
5. Seo JW, Park IW. Intravitreal bevacizumab for treatment of diabetic macular edema. Korean J Ophthalmol. 2009. 23:17–22.
6. Velez-Montoya R, Fromow-Guerra J, Burgos O, et al. The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study. Retina. 2009. 29:20–26.
7. Chung EJ, Hong YT, Lee SC, et al. Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2008. 246:1241–1247.
8. Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol. 2002. 160:501–509.
9. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004. 25:581–611.
10. Klein R, Sharrett AR, Klein BE, et al. Are retinal arteriolar abnormalities related to atherosclerosis?: The Atherosclerosis Risk in Communities Study. Arterioscler Thromb Vasc Biol. 2000. 20:1644–1650.
11. Ikram MK, de Jong FJ, Vingerling JR, et al. Are retinal arteriolar or venular diameters associated with markers for cardiovascular disorders? The Rotterdam Study. Invest Ophthalmol Vis Sci. 2004. 45:2129–2134.
12. Klein R, Klein BE, Knudtson M, et al. Are inflammatory factors related to retinal vessel caliber? The Beaver Dam Eye Study. Arch Ophthalmol. 2006. 124:87–94.
13. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006. 26:999–1005.
14. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007. 114:743–750.
15. Nguyen TT, Wang JJ, Sharrett AR, et al. Relationship of retinal vascular caliber with diabetes and retinopathy: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2008. 31:544–549.
16. Fischer S, Renz D, Schaper W, Karliczek GF. In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor. Eur J Pharmacol. 2001. 411:231–243.
17. Wickremasinghe SS, Rogers SL, Gillies MC, et al. Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Invest Ophthalmol Vis Sci. 2008. 49:4707–4711.
18. Knudtson MD, Lee KE, Hubbard LD, et al. Revised formulas for summarizing retinal vessel diameters. Curr Eye Res. 2003. 27:143–149.
19. Fukumura D, Gohongi T, Kadambi A, et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A. 2001. 98:2604–2609.
20. Goel N, Kumar V, Ghosh B. Ischemic maculopathy following intravitreal bevacizumab for refractory diabetic macular edema. Int Ophthalmol. 2011. 31:39–42.
21. Lee SJ, Koh HJ. Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (avastin) with pars plana vitrectomy. J Ocul Pharmacol Ther. 2009. 25:173–174.
22. Chen E, Hsu J, Park CH. Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2009. 40:68–70.
TOOLS
Similar articles